POLYPEPTIDE GROUP AG |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 33.72 CHF | +2.66% |
|
+2.12% | +92.35% |
| Mar. 12 | PolyPeptide Group AG Provides Earnings Guidance for 2024 | CI |
| Mar. 12 | Transcript : PolyPeptide Group AG, 2023 Earnings Call, Mar 12, 2024 |
Valuation
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Capitalization 1 | 4,371 | 842.2 | 620.9 | 1,094 | - | - |
| Enterprise Value (EV) 1 | 4,264 | 836.4 | 620.9 | 1,167 | 1,210 | 1,242 |
| P/E ratio | 90 x | 107 x | -12.1 x | -126 x | 64.6 x | 28.8 x |
| Yield | 0.22% | - | - | - | 0.13% | 0.58% |
| Capitalization / Revenue | 15.5 x | 3 x | 1.91 x | 3.13 x | 2.66 x | 2.25 x |
| EV / Revenue | 15.1 x | 2.98 x | 1.91 x | 3.34 x | 2.94 x | 2.55 x |
| EV / EBITDA | 50.3 x | 21.6 x | -103 x | 42.6 x | 18.6 x | 12.1 x |
| EV / FCF | -257 x | -11.4 x | - | -25.3 x | -92.4 x | -103 x |
| FCF Yield | -0.39% | -8.76% | - | -3.96% | -1.08% | -0.97% |
| Price to Book | 10.1 x | 2 x | - | 2.79 x | 2.65 x | 2.44 x |
| Nbr of stocks (in thousands) | 33,031 | 32,938 | 32,944 | 32,970 | - | - |
| Reference price 2 | 132.3 | 25.57 | 18.85 | 33.17 | 33.17 | 33.17 |
| Announcement Date | 3/15/22 | 3/14/23 | 3/12/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 223 | 282.1 | 281 | 324.9 | 349.5 | 411.2 | 487 |
| EBITDA 1 | - | 84.8 | 38.67 | -6 | 27.4 | 64.87 | 102.4 |
| EBIT 1 | - | 64.2 | 12.61 | -36.47 | -4.091 | 30.16 | 61.6 |
| Operating Margin | - | 22.76% | 4.49% | -11.23% | -1.17% | 7.33% | 12.65% |
| Earnings before Tax (EBT) 1 | - | 59.85 | 7.567 | -58.24 | -12.55 | 17.7 | 41.6 |
| Net income 1 | 31.34 | 47.26 | 7.767 | -51.44 | -12.22 | 14.9 | 38.43 |
| Net margin | 14.05% | 16.75% | 2.76% | -15.83% | -3.5% | 3.62% | 7.89% |
| EPS 2 | - | 1.470 | 0.2400 | -1.560 | -0.2624 | 0.5134 | 1.152 |
| Free Cash Flow 1 | - | -16.61 | -73.3 | - | -46.2 | -13.1 | -12.1 |
| FCF margin | - | -5.89% | -26.09% | - | -13.22% | -3.19% | -2.48% |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | 0.2909 | - | - | - | 0.0444 | 0.1918 |
| Announcement Date | 3/15/21 | 3/15/22 | 3/14/23 | 3/12/24 | - | - | - |
1EUR in Million2EUR
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 S1 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|---|---|
| Net sales 1 | 135.1 | 133.7 | 147.3 | 131.8 | 191.5 | 131.8 | 212.6 |
| EBITDA 1 | 39.89 | 26.71 | - | -19.39 | 13.4 | 0.7 | 26.8 |
| EBIT 1 | - | 15.48 | - | - | -2.004 | -14.9 | 10.7 |
| Operating Margin | - | 11.58% | - | - | -1.05% | -11.31% | 5.03% |
| Earnings before Tax (EBT) | - | - | - | - | - | - | - |
| Net income 1 | - | 10.25 | -2.48 | -34.27 | - | -19.8 | 8.7 |
| Net margin | - | 7.67% | -1.68% | -25.99% | - | -15.02% | 4.09% |
| EPS | - | 0.3100 | - | -1.040 | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - |
| Announcement Date | 8/17/21 | 8/18/22 | 3/14/23 | 8/15/23 | 3/12/24 | - | - |
1EUR in Million
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|
| Net Debt 1 | - | - | - | - | 73.6 | 116 | 148 |
| Net Cash position 1 | - | 107 | 5.8 | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | 2.687 x | 1.79 x | 1.444 x |
| Free Cash Flow 1 | - | -16.6 | -73.3 | - | -46.2 | -13.1 | -12.1 |
| ROE (net income / shareholders' equity) | - | 16.7% | 1.84% | - | -2.49% | 4.35% | 9.85% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - |
| Book Value Per Share 2 | - | 13.10 | 12.80 | - | 11.90 | 12.50 | 13.60 |
| Cash Flow per Share 2 | - | 1.780 | 0.1700 | - | 0.5800 | 1.500 | 2.740 |
| Capex 1 | - | 74 | 78.8 | - | 60.4 | 69.9 | 80.8 |
| Capex / Sales | - | 26.22% | 28.03% | - | 17.3% | 16.99% | 16.6% |
| Announcement Date | 3/15/21 | 3/15/22 | 3/14/23 | 3/12/24 | - | - | - |
1EUR in Million2EUR
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
HOLD
Number of Analysts
5
Last Close Price
33.17
EUR
Average target price
25.12
EUR
Spread / Average Target
-24.27%
EPS Revisions
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| +92.35% | 1.19B | |
| +37.74% | 723B | |
| +34.68% | 595B | |
| -2.07% | 369B | |
| +20.25% | 332B | |
| +2.99% | 282B | |
| +17.11% | 244B | |
| +10.02% | 208B | |
| -4.05% | 205B | |
| +7.43% | 166B |
- Stock Market
- Equities
- PPGN Stock
- Financials PolyPeptide Group AG
